Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies

Latha Shivakumar, Stephen Maxted Ansell

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

B-lymphocyte stimulator/B-cell activating factor (BLyS/BAFF) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis family of ligands, are expressed by monocytes, macrophages, and dendritic cells, and increased expression of these ligands is noted in lymphomas and plasma cell malignancies. BLyS and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BLyS or APRIL or the receptors B-cell maturation, transmembrane activator and calcium-modulating cyclophilin ligand interactor, or BAFF-R have been reported in various B-cell malignancies, including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenström's macroglobulinemia. Levels of BLyS (in the tumor and in the serum) increased with the transformation of the tumors to a more aggressive phenotype. A high BLyS level inversely correlated with a poor median overall survival, presence of constitutional symptoms, and increased levels of lactate dehydrogenase in patients with non-Hodgkin's lymphoma. Additionally, patients who responded to therapy had a lower BLyS level than those with progressive disease. Several agents targeting BLyS and APRIL are currently being pursued in phase I clinical studies in patients with B-cell malignancies.

Original languageEnglish (US)
Pages (from-to)106-108
Number of pages3
JournalClinical Lymphoma and Myeloma
Volume7
Issue number2
StatePublished - Sep 2006

Fingerprint

B-Cell Activating Factor
Hematologic Neoplasms
Ligands
B-Lymphocytes
Neoplasms
Non-Hodgkin's Lymphoma
Cyclophilins
Waldenstrom Macroglobulinemia
Survival
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Plasma Cells
Multiple Myeloma
Hodgkin Disease
L-Lactate Dehydrogenase
Dendritic Cells
Monocytes
Lymphoma
Necrosis
Macrophages

Keywords

  • Belimumab
  • Chronic lymphocytic leukemia
  • Hodgkin's lymphoma
  • Multiple myeloma
  • Non-Hodgkin's lymphoma
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

@article{d1515cc7fe23450ba63ec27e8cd408c0,
title = "Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies",
abstract = "B-lymphocyte stimulator/B-cell activating factor (BLyS/BAFF) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis family of ligands, are expressed by monocytes, macrophages, and dendritic cells, and increased expression of these ligands is noted in lymphomas and plasma cell malignancies. BLyS and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BLyS or APRIL or the receptors B-cell maturation, transmembrane activator and calcium-modulating cyclophilin ligand interactor, or BAFF-R have been reported in various B-cell malignancies, including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenstr{\"o}m's macroglobulinemia. Levels of BLyS (in the tumor and in the serum) increased with the transformation of the tumors to a more aggressive phenotype. A high BLyS level inversely correlated with a poor median overall survival, presence of constitutional symptoms, and increased levels of lactate dehydrogenase in patients with non-Hodgkin's lymphoma. Additionally, patients who responded to therapy had a lower BLyS level than those with progressive disease. Several agents targeting BLyS and APRIL are currently being pursued in phase I clinical studies in patients with B-cell malignancies.",
keywords = "Belimumab, Chronic lymphocytic leukemia, Hodgkin's lymphoma, Multiple myeloma, Non-Hodgkin's lymphoma, Waldenstr{\"o}m's macroglobulinemia",
author = "Latha Shivakumar and Ansell, {Stephen Maxted}",
year = "2006",
month = "9",
language = "English (US)",
volume = "7",
pages = "106--108",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies

AU - Shivakumar, Latha

AU - Ansell, Stephen Maxted

PY - 2006/9

Y1 - 2006/9

N2 - B-lymphocyte stimulator/B-cell activating factor (BLyS/BAFF) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis family of ligands, are expressed by monocytes, macrophages, and dendritic cells, and increased expression of these ligands is noted in lymphomas and plasma cell malignancies. BLyS and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BLyS or APRIL or the receptors B-cell maturation, transmembrane activator and calcium-modulating cyclophilin ligand interactor, or BAFF-R have been reported in various B-cell malignancies, including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenström's macroglobulinemia. Levels of BLyS (in the tumor and in the serum) increased with the transformation of the tumors to a more aggressive phenotype. A high BLyS level inversely correlated with a poor median overall survival, presence of constitutional symptoms, and increased levels of lactate dehydrogenase in patients with non-Hodgkin's lymphoma. Additionally, patients who responded to therapy had a lower BLyS level than those with progressive disease. Several agents targeting BLyS and APRIL are currently being pursued in phase I clinical studies in patients with B-cell malignancies.

AB - B-lymphocyte stimulator/B-cell activating factor (BLyS/BAFF) and a proliferation-inducing ligand (APRIL), members of the tumor necrosis family of ligands, are expressed by monocytes, macrophages, and dendritic cells, and increased expression of these ligands is noted in lymphomas and plasma cell malignancies. BLyS and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BLyS or APRIL or the receptors B-cell maturation, transmembrane activator and calcium-modulating cyclophilin ligand interactor, or BAFF-R have been reported in various B-cell malignancies, including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenström's macroglobulinemia. Levels of BLyS (in the tumor and in the serum) increased with the transformation of the tumors to a more aggressive phenotype. A high BLyS level inversely correlated with a poor median overall survival, presence of constitutional symptoms, and increased levels of lactate dehydrogenase in patients with non-Hodgkin's lymphoma. Additionally, patients who responded to therapy had a lower BLyS level than those with progressive disease. Several agents targeting BLyS and APRIL are currently being pursued in phase I clinical studies in patients with B-cell malignancies.

KW - Belimumab

KW - Chronic lymphocytic leukemia

KW - Hodgkin's lymphoma

KW - Multiple myeloma

KW - Non-Hodgkin's lymphoma

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=33750191271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750191271&partnerID=8YFLogxK

M3 - Article

C2 - 17026820

AN - SCOPUS:33750191271

VL - 7

SP - 106

EP - 108

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -